Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Biopharma has outperformed the broader market this year—the SPDR S&P Biotech ETF (XBI) is up 26% and the SPDR S&P Pharmaceuticals ETF (XPH) 22% while the S&P 500 has slipped more than 3% in a recent four-day slide—driven by a wave of strategic pricing pacts with the U.S. government, big-ticket M&A and stronger clinical readouts. Notable moves include Eli Lilly’s 33% YTD gain as it approaches a $1 trillion valuation, Pfizer securing a TrumpRx deal and an up-to-$10 billion bid for Metsera, Merck’s $9.2 billion purchase of Cidara, and J&J’s $3 billion bid for Halda (J&J shares are up ~40% in 2025), while Ernst & Young reports average deal sizes are about 90% larger than last year despite fewer transactions. Combined with the Fed’s September rate cut, selective positive trial data (e.g., Olema surging 150% after Genentech Phase 3 results) and resilient device names such as Medtronic, the sector is becoming leaner and more acquisition-focused, signaling renewed investor appetite for late‑stage assets and larger strategic deals.

Analysis

Biopharma has materially outperformed the broader market year-to-date: the SPDR S&P Biotech ETF (XBI) is up 26% and the SPDR S&P Pharmaceuticals ETF (XPH) is up 22%, while the S&P 500 slid more than 3% over a recent four-day stretch and is trading below its earlier YTD peak (up less than 13% after reaching +17.2% three weeks ago). Large-cap drugmakers are driving much of the re-rating—Eli Lilly (LLY) is up 33% YTD and approaching a $1 trillion valuation on momentum around weight‑loss drugs and a Trump administration agreement to allow Medicare sales of Zepbound plus three years of tariff relief.

M&A and government pricing pacts are clear catalysts: Pfizer secured a TrumpRx deal and an up-to-$10 billion acquisition of Metsera, Merck bought Cidara for $9.2 billion, and Johnson & Johnson bid $3 billion for Halda; EY notes average 2025 biopharma deal sizes are ~90% larger than a year ago despite fewer transactions. Positive late‑stage clinical readouts have amplified moves (Olema jumped >150% after Genentech Phase 3 data) and device names such as Medtronic (MDT) cited “robust” volumes and raised 2026 guidance, supporting sector breadth (XLV +11% YTD, +12% over three months).

Implications include a leaner, more acquisition‑driven ecosystem that favors companies with late‑stage assets and explicit government arrangements, but the market now exhibits binary event risk and valuation dispersion between winners and laggards (J&J +40% in 2025 vs. Merck -3%). Investors should monitor near‑term catalysts (trial readouts, announced deals), regulatory/policy developments around pricing and tariffs, and the Federal Reserve’s path, as these factors will likely drive episodic volatility and deal activity going forward.

Key Decisions for Investors

• Consider selectively overweighting high‑quality, large‑cap drugmakers and targeted biotech exposure (via XBI/XPH) that have secured pricing deals or late‑stage assets—examples cited include LLY, PFE and JNJ—while maintaining position size discipline
• Favor event‑driven sizing and active selection around near‑term catalysts (late‑stage readouts and announced M&A) and use options or stop limits to manage binary trial risk highlighted by moves like OLMA's 150% spike
• Monitor policy and macro indicators closely—any reversal in drug‑pricing negotiations, tariff concessions, or a change in the Fed narrative could quickly reprice the sector, so be prepared to trim exposure if broader equity weakness resumes